PHARMACOLOGICAL CLASSIFICATION: A 10.2.2 Medicines acting on respiratory system - Other.
PHARMACOLOGICAL ACTION: Theophylline with ethylenediamine and ephedrine hydrochloride act additively to stimulate respiration and relax the bronchial muscles in bronchial spasm. Phenobarbitone is added to counteract the combined central stimulant actions of the above mentioned drugs.
INDICATIONS: For the symptomatic relief of bronchial spasm associated with asthma, bronchial asthma, bronchopneumonia and bronchitis. It may be given over prolonged periods to reduce the number and severity of attacks.
CONTRA-INDICATIONS: Patients with coronary thrombosis, hypertension, porphyria and thyrotoxicosis, and those receiving monoamine oxidase inhibitors.
DOSAGE AND DIRECTIONS FOR USE: One to two tablets or as prescribed.
Not for children under 12 years of age.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS: Side-effects may include gastric irritation with nausea and vomiting. Some patients exhibit an idiosyncrasy to phenobarbitone and in such individuals, phenobarbitone may cause restlessness and excitement
Natrophylline Compound tablets should be administered with caution to patients suffering from cardiac disease and impaired liver or renal function.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT: Overdosage with Natrophylline Compound tablets may cause nausea, vomiting, gastro-intestinal bleeding and palpitations.
In cases of severe toxicity, the stomach should be emptied by gastric lavage. Respiration and electrolyte balance should be maintained.
IDENTIFICATION: Dark brown, sugar coated tablets.
PRESENTATION: Packs of 5000 tablets.
STORAGE INSTRUCTIONS: Store below 25°C.
Protect from light and moisture
KEEP OUT OF REACH OF CHILDREN.
APPLICATION NUMBER: G535 (Act 101/1965).
NAME AND BUSINESS ADDRESS OF APPLICANT: Lennon Limited
7 Fairclough Road
PORT ELIZABETH 6001